Amgen Inc. (NASDAQ:AMGN) is one of the 10 Most Profitable S&P 500 Stocks to Buy Now. On March 19, 2026, Wells Fargo raised the price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $375 and maintained ...
Zacks Investment Research on MSN
Amgen (AMGN) outpaces stock market gains: What you should know
Amgen (AMGN) closed at $353.93 in the latest trading session, marking a +1.58% move from the prior day. This move outpaced the S&P 500's daily gain of 0.54%. At the same time, the Dow added 0.66%, and ...
Amgen Inc. AMGN and GSK plc GSK are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set ...
The White House’s direct-to-consumer (DTC) platform, TrumpRx, is steadily expanding its catalogue, with products from GSK and Amgen the latest to join the collection of drugs offered through the pr | ...
Amgen stock soared as much as 16% on Friday after it reported first-quarter earnings. The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug could be ...
Why Amgen (AMGN) is on investors’ radar today Amgen (AMGN) is back in focus after recent share price moves, with the stock ...
The competition for treatments in the weight-loss market is heating up. Amgen is currently working on a promising anti-obesity medicine. There are plenty of other excellent reasons to buy the stock ...
A U.S. lawmaker is accusing Amgen of “putting profits before patients” over its decision to continue marketing a high dose of a pricey cancer treatment instead of a lower dose that is less expensive ...
Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IRS.
Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...
15d
Amgen Touts 2025 Double-Digit Growth, MariTide Obesity Push and BiTE Momentum at Leerink Conference
Executives from Amgen (NASDAQ:AMGN) highlighted broad-based commercial growth, a set of six “key growth drivers,” and several late-stage pipeline programs during a conference session hosted by Leerink ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results